Revelation Biosciences Inc (REVB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Revelation Biosciences Inc (REVB) has a cash flow conversion efficiency ratio of -0.248x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.21 Million) by net assets ($12.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See REVB equity to assets ratio to measure how much of total assets are equity-financed.
Revelation Biosciences Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Revelation Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check REVB cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Revelation Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Revelation Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Smart Equity AG
HM:SE3
|
N/A |
|
Noroo Holdings Co Ltd
KO:000325
|
-0.023x |
|
Cipta Selera Murni Pt
JK:CSMI
|
-0.068x |
|
Eneco Refresh Ltd
AU:ERG
|
0.146x |
|
Merko Gida Sanayi ve Ticaret AS
IS:MERKO
|
-0.019x |
|
coinIX GmbH & Co. KGaA
DU:XCX
|
N/A |
|
Variscan Mines Ltd
AU:VAR
|
-0.057x |
|
Kakel Max AB (publ)
ST:KAKEL
|
-0.012x |
Annual Cash Flow Conversion Efficiency for Revelation Biosciences Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Revelation Biosciences Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Revelation Biosciences Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $8.86 Million | $-8.27 Million | -0.933x | +76.02% |
| 2024-12-31 | $4.71 Million | $-18.32 Million | -3.891x | -255.02% |
| 2023-12-31 | $6.65 Million | $-7.29 Million | -1.096x | +89.72% |
| 2022-12-31 | $1.05 Million | $-11.22 Million | -10.660x | -109.56% |
| 2021-12-31 | $-99.47K | $-11.09 Million | 111.497x | +176962.24% |
| 2020-12-31 | $3.41 Million | $-215.07K | -0.063x | +100.00% |
| 2019-12-31 | $-3.64K | $41.09 Million | -11293.568x | -9182593.30% |
| 2018-12-31 | $264.89 Million | $32.58 Million | 0.123x | -4.50% |
| 2017-12-31 | $188.28 Million | $24.25 Million | 0.129x | +87.38% |
| 2016-12-31 | $168.76 Million | $11.60 Million | 0.069x | -- |
About Revelation Biosciences Inc
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregul… Read more